PRS

23andMe Launches New Genetic Report on Bipolar Disorder

Retrieved on: 
onsdag, juni 5, 2024
PRS, Anxiety, CDC, Research, Mental health, Science, Database, Bipolar disorder, Doctor of Philosophy, Genetics, SAN, Depression, Genomic Health, Premium, MD, Mania, Behavior, 23andMe

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition.
  • The Bipolar Disorder PRS report calculates the likelihood of an individual being diagnosed with the condition based on thousands of different genetic variants, as well as a customer’s genetic ancestry and birth sex.
  • Knowing a person’s genetic likelihood for developing bipolar disorder can help identify potential symptoms early on,” said Noura Abul-Husn, MD, PhD, Vice President of Genomic Health at 23andMe.
  • To learn more about the new 23andMe Bipolar Disorder report and how to become a 23andMe+ Premium member, visit https://www.23andme.com/membership/ .

23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community

Retrieved on: 
tisdag, juni 4, 2024
PRS, Incidence, Colorectal Cancer Alliance, Genetics, Research, Colorectal cancer, Large intestine, Lead, Cancer, System, Mortality, African Americans, Disease, Partnership, Risk, Premium, Rectum, Doctor of Philosophy, Woman, Dairy

SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community.

Key Points: 
  • SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community.
  • In the United States, Black and African Americans tend to experience earlier onset and worse disease outcomes for colorectal cancer.
  • Colorectal cancer is the third most common cancer among men and women in the Black community.
  • “At the Alliance, we empower people to better navigate colorectal cancer outcomes in their lives and communities,” said Angele Russell, Senior Director of Partnerships & Health Equity at the Colorectal Cancer Alliance.

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

Retrieved on: 
måndag, juni 3, 2024
Genetics, PRS, Breast cancer, MYGN, ACMG, American College, Calibration, Population health, Woman, Myriad Genetics, Risk, Genetic testing, Medical genetics, Epidemiology, Risk assessment, Breast MRI, Physician, MRI, Genetics in Medicine, Classification

RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator.

Key Points: 
  • RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator.
  • The study demonstrated that RiskScore was more accurate at stratifying women at high- or low-risk of developing breast cancer than the Tyrer-Cuzick risk calculator alone.
  • “Key findings include the superior calibration and discrimination of the PRS, out-performing standard breast cancer risk models, in a large, real-world medical claims dataset.
  • “Comprehensive and equitable personalized breast cancer risk assessment integrates known traditional risk factors, germline-mutation testing, and an all-ancestry PRS.

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

Retrieved on: 
söndag, juni 2, 2024
Cancer, IO, Interim, CD137, Glioblastoma, Liver, PD-L1, Patient, Annual general meeting, NSCLC, Immunotherapy, Society, Pembrolizumab, Sarcoma, Head, Stomach, Lung cancer, PRS, RDE

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
  • “MCLA-145 as monotherapy or with pembrolizumab appears to have a manageable safety profile and early clinical activity in these difficult to treat cancers.
  • Pts treated with the combination of MCLA-145 and pembrolizumab had cancers that either relapsed after PD-(L)1 therapies or were immunotherapy (IO) naïve.
  • per investigator assessment
    MCLA-145 monotherapy or in combination with pembrolizumab had a well-tolerated and manageable safety profile at the RDE, 40mg Q3W
    Liver toxicity, a common CD137 related adverse event, was controlled with no G4 events observed at Q3W

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

Retrieved on: 
lördag, juni 1, 2024
Webcast, EDT, Patient, Cancer, EGFR, Yonsei University, PFS, Lung cancer, Progression-free survival, Neoplasm, PRS, CDT, Pharmaceutical industry

As of the updated data cutoff on May 13, 2024 for the 17 EGFRwt patients previously reported on, 15 patients were response-evaluable.

Key Points: 
  • As of the updated data cutoff on May 13, 2024 for the 17 EGFRwt patients previously reported on, 15 patients were response-evaluable.
  • In addition, 8 patients achieved stable disease (SD), resulting in a disease control rate of 71%.
  • The combination of AFM24 with atezolizumab showed encouraging signals of clinical activity including 1 CR, 3 PRs and 6 patients with SD.
  • “The efficacy of the combination of AFM24 and atezolizumab in these heavily pretreated NSCLC patients is encouraging and supports our hypothesis of a synergistic activity of AFM24 with PD-1/PD-L1 blockade.

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

Retrieved on: 
lördag, juni 1, 2024
Therapy, ASCO, Toxicity, Patient, Annual general meeting, Cancer, Immunotherapy, Society, HD, Pembrolizumab, Neoplasm, Poster, PRS, Pharmaceutical industry

In addition, the combination of WTX-124 with pembrolizumab was generally well-tolerated, which alongside compelling biomarker activity, suggests the potential for combination efficacy.

Key Points: 
  • In addition, the combination of WTX-124 with pembrolizumab was generally well-tolerated, which alongside compelling biomarker activity, suggests the potential for combination efficacy.
  • Increased T cell activation signature for the combination suggests a potential for improved antitumor activity by combining WTX-124 with pembrolizumab.
  • Werewolf will host a webcast at 8:00 am ET on Monday, June 3, 2024, to review these clinical results presented at ASCO.
  • Werewolf management will be joined by study investigator Justin Moser, M.D., Associate Clinical Investigator, HonorHealth Research Institute, Scottsdale, AZ, who will present the updated data.

CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination

Retrieved on: 
söndag, juni 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MD, CRS, Partial, UC, ASCO, RECIST, Hepatocellular carcinoma, Carcinoma, PD-L1, Patient, Nivolumab, Serum, Universidad, ESMO, NSCLC, Simple squamous epithelium, Safety, Society, Dor, PR, Immunology, Doctor of Philosophy, CPI, Lung cancer, CIMA, CXCL10, HCC, CXCL9, Tumor microenvironment, Congress, PRS, Pharmaceutical industry

Visugromab is a monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), a central mediator of immune resistance to cancer therapies.

Key Points: 
  • Visugromab is a monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), a central mediator of immune resistance to cancer therapies.
  • Partial responses (PRs): 5/11 patients who achieved PR had no RECIST 1.1 response at all on prior CPI treatments.
  • “We have designed a broad Phase 2b development plan to thoroughly investigate where visugromab can have its biggest impact for patients.
  • Title: Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer

IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST

Retrieved on: 
måndag, juni 3, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ASCO, RECIST, Vomiting, Patient, Fatigue, Mutation, Diarrhea, Strategist, Annual general meeting, KIT, Data, Exon, Safety, Hypertension, Society, UZ Leuven, Appetite, DNA, Circulating tumor DNA, Infrared spectroscopy correlation table, First grade, Death, TKI, Dysgeusia, BID, Neoplasm, GIST, PRS, Nausea, Pharmaceutical industry

These data will be highlighted today in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • These data will be highlighted today in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • “There is a significant unmet medical need for next-generation therapies for GIST patients.
  • 74% of patients remained on study treatment, and the median duration of treatment was 16 weeks as of the data cut-off.
  • “In this dataset, IDRx has presented preliminary proof-of-concept of IDRX-42 supporting its potentially best-in-class profile in patients with GIST,” said Tim Clackson, Ph.D., Chief Executive Officer of IDRx.

Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer

Retrieved on: 
fredag, maj 31, 2024
Patient, CRS, API, Food, Immune system, FDA, AACR, IND, Neoplasm, PRS, Prostate cancer, Freezing, Lysis, Pharmaceutical industry

FORT LAUDERDALE, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T, an in situ personalized therapy platform optimized for solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SYNC-T SV-102, its lead candidate for the treatment of patients with metastatic castrate-resistant prostate cancer.

Key Points: 
  • "Receiving clearance of our IND is a significant milestone for Syncromune and will allow us to rapidly advance the clinical development of SYNC-T SV-102," said Syncromune’s President and CEO, Eamonn Hobbs.
  • "This clearance, following our recent presentation at AACR of data demonstrating unprecedented response rates, underscores the potential of SYNC-T SV-102 to change the landscape of prostate cancer treatment."
  • "The prospects of this new combination multi-target approach and its broad potential applicability in the treatment of metastatic solid tumor cancers is incredibly exciting."
  • The combination approach is designed to promote T cell activation and proliferation, empowering the immune system to recognize and attack patient-specific cancer throughout the body.

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

Retrieved on: 
torsdag, maj 30, 2024
ICI, Patient, Liver disease, Pembrolizumab, Ovarian cancer, TME, Colorectal cancer, MSI-L, ECM, Safety, Diarrhea, MSS, PRS, Assistant, Cancer, Infiltration, ASCO, CRC, Fatigue, Society, Aes, Immunotherapy, DCR, Annual general meeting, Johns Hopkins, Pharmaceutical industry

The poster presentation highlights the safety and tolerability of doses between 30-200 mg of NC410 in combination with 400 mg of pembrolizumab.

Key Points: 
  • The poster presentation highlights the safety and tolerability of doses between 30-200 mg of NC410 in combination with 400 mg of pembrolizumab.
  • The combination resulted in partial responses (PR) and stable disease in both CRC and ovarian cancer.
  • “While MSS/MSI-L CRC and ovarian cancer are difficult to treat and recalcitrant to immunotherapy, the combination of NC410 and pembrolizumab demonstrated clinical activity against both tumor types.
  • Details of the presentation are as follows:
    Title: A Phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer